The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
The 23-Valent Pneumococcal Polysaccharide Vaccine. Part I. Efficacy of PPV in the Elderly: A Comparison of Meta-Analyses
Abstract
A 23-valent polysaccharide pneumococcal vaccine (PPV) has been available in the UK for more than 20 years and is currently recommended for use in high-risk groups (HRG) of 2+ years of age. The degree of protection afforded by the PPV remains a critical issue, although a number of randomised clinical trials and case-control studies (CCS) have been published. The aim of this work is to review the estimates on the efficacy of PPV against pneumococcal pneumonia and invasive pneumococcal disease (IPD) in the elderly and to perform a meta-analysis in order to obtain a pooled estimate of the level of protection in high and low risk individuals. These two groups of individuals are at the centre of the current debate on whether or not to extend the vaccination programme to all elderly individuals 65+. Only randomised and quasi-randomised studies are included in the analysis and results are compared with previous meta-analyses. The effect of the inclusion of observational studies is investigated in the sensitivity analysis. When taken with the results of other meta-analyses and observational studies, it appears that PPV offers protection against IPD in the general elderly population (VE = 65%; 95% CI: -49-92%) whereas it has a moderate effect in the high-risk elderly (VE = 20%; 95% CI: -188-78%). The vaccine has little or no effect against pneumonia (VE = 16% in the general elderly and -20% in HRG).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The immune system changes with age in nearly every aspect, generally resulting in a decline in pathogen immunity with increased age.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [3]
In the citing paper
“ageing is associated with high morbidity and mortality rates for various infections and significant reductions in vaccine efficacy1-6”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [3]
In the citing paper
“A 23-valent polysaccharide vaccine against Streptococcus pneumoniae has been used for many years in the older population. Meta-analyses reported efficacy against invasive disease, but the efficacy against pneumonia is frequently in doubt, as results from clinical studies are inconclusive [167].”
From Aging of the immune system: Focus on inflammation and vaccination (2016) · cites this paper as [167]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,557
The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide Vaccine
Shapiro, E. D., Berg, A. T., AUSTRIAN, R. C., Schroeder, D., Parcells, V., Margolis, A., Adair, R. K., & Clemens, J. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252101 · Cited by 1,050
(1997) · PsycEXTRA Dataset · doi:10.1037/e547512006-001 · Cited by 999
Users' Guides to the Medical Literature
Oxman, A. D. (1994) · JAMA · doi:10.1001/jama.1994.03520170077040 · Cited by 925
Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations
Butler, J. C. (1993) · JAMA · doi:10.1001/jama.270.15.1826 · Cited by 674
Oxman, A. D. (1994) · JAMA · doi:10.1001/jama.272.17.1367 · Cited by 486
7. Prevention of Pneumococcal Pneumonia by Vaccination
AUSTRIAN, R. C., Douglas, R. M., Schiffman, G., Coetzee, A., KOORNHOF, H. J., Hayden-Smith, S., & Reid, R. D. W. (1985) · University of Pennsylvania Press eBooks · doi:10.9783/9781512800135-009 · Cited by 401
Research works printed but not linked: 3
- Salisbury DM, Begg NT. Immunisation against infectious disease, Bicentenary Edition. London: HMSO, 1996.
- Johan Giesecke. Modern Infectious Disease Epidemiology. London: Edward Arnold, 1994.
- Gaillat J, Zmirou D, Mallaret MR, Rouhan D, Bru JP, Stahl JP et al. Essai clinique du vaccin antipneumococcique chez des personnes agees vivant en institution. Rev Epidem Sante Publ 1985; 33: 437-444.
Cited by
Sorted by citations
Items 101–185 of 185
Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland
Grzesiowski, P., Aguiar‐Ibáñez, R., Kobryń, A., Durand, L., & Puig, P.-E. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21571 · Cited by 17
“Therefore, it may be expected that the ICER for vaccinating the very old is less attractive than that for the total 65+ population.(6,24,25) When the HCS scenario was analysed, vaccination was seen to be an even more cost-effective strategy (PLN838 and PLN2,160 per QALY gained for high-risk elderly HR and all elderly…”
BackgroundStatement on the Use of Conjugate Pneumococcal Vaccine – 13 Valent in Adults (Pneu-C-13)
Quach, C., & Thomas, M. (2013) · Canada Communicable Disease Report · doi:10.14745/ccdr.v39i00a05 · Cited by 17
Martinelli, D., Tafuri, S., Caputi, G., Fortunato, F., Reggio, P., Germinario, C. A., & Prato, R. (2010) · American Journal of Infection Control · doi:10.1016/j.ajic.2009.09.019 · Cited by 17
“Melegaro and Edmunds, in a metaanalysis (2004), showed that PPV23 offers protection against IPD in the general elderly population (vaccine efficacy 5 65%).(14) More critical is to evaluate the effectiveness of this vaccination in preventing pneumonia: in a matched case-control study published in 2009 by Vila-Corcoles…”
BackgroundMeta-analyses on Pediatric Infections and Vaccines
Grammatikos, A. P., Mantadakis, E., & Falagas, M. E. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.01.008 · Cited by 16
“However, two other meta-analyses conclude that the PPV vaccine is indeed protective in the elderly and in those with chronic diseases.(149,150)”
ResultProbiotics as Anti-immunosenescence Agents
Sharma, R., Kapila, R., & Kapila, S. (2013) · Food Reviews International · doi:10.1080/87559129.2012.751547 · Cited by 16
“(97) Several reports have shown decreased antibody response to various vaccines in old age, including influenza vaccine,(98) hepatitis B vaccine,(99) and pneumococcal polysaccharides.(100) Furthermore, the antibody responses have been reported to be of shorter duration in the elderly as compared with young adults.”
BackgroundSpray-dried pneumococcal membrane vesicles are promising candidates for pulmonary immunization
Mehanny, M., Boese, A. S., Bornamehr, B., Hoppstädter, J., Presser, V., Kiemer, A. K., Lehr, C., & Fuhrmann, G. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121794 · Cited by 16
Balmer, P., Borrow, R., & Arkwright, P. D. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.021 · Cited by 16
Katsurahara, T., Hotomi, M., Yamauchi, K., Billal, D. S., & Yamanaka, N. (2008) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-008-0647-7 · Cited by 16
Vila-Córcoles, Á., Gondar, O. O., Rodríguez-Blanco, T., Gutierrez-Perez, A., Vila-Rovira, Á., & EPIVAC Study Group (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.19466 · Cited by 15
“Furthermore, our point estimates of the adjusted vaccine effectiveness against bacteremic pneumonia due to vaccine serotypes (49%) fits with data reported in most prior meta-analyses, which reported a vaccine effectiveness of approximately 40–60% against IPD among immunocompetent people over 50 y.(6-8) Definitive pneu…”
BackgroundResultInfluentialWorkshop on Immunizations in Older Adults: Identifying Future Research Agendas
High, K. P., D’Aquila, R. T., Fuldner, R., Gerding, D. N., Halter, J. B., Haynes, L., Hazzard, W. R., Jackson, L. A., Janoff, E. N., Levin, M. J., et al. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02772.x · Cited by 15
Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview
Vila-Córcoles, Á., & Gondar, O. O. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.176 · Cited by 14
Smith, K. J., Zimmerman, R. K., Nowalk, M. P., & Roberts, M. S. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.059 · Cited by 13
Carbohydrate‐Based Antibacterial Vaccines
Pon, R. A., & Jennings, H. J. (2008) · Wiley eBooks · doi:10.1002/9780470473283.ch4 · Cited by 14
Crowe, S., Utley, M., Walker, G., Grove, P., & Pagel, C. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.04.034 · Cited by 13
History of Pneumococcal Immunization
Mäkelä, P. H., & Butler, J. C. (2014) · ASM Press eBooks · doi:10.1128/9781555815820.ch2 · Cited by 13
Regev‐Yochay, G., Rahav, G., Riesenberg, K., Weil‐Weiner, Y., Strahilevitz, J., Stein, M., Glikman, D., Weber, R., Potasman, I., Dagan, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088406 · Cited by 12
“Yet, the efficacy and effectiveness of PPSV23 in these populations are controversial [2,3].”
BackgroundGouveia, M. R. D. A., Jesus, G., Mónica, I. B., da Costa, J. F. S., & Borges, M. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1560769 · Cited by 12
Ariñez-Fernandez, M. C., Carrasco‐Garrido, P., Carballo, M. M. G., Hernández‐Barrera, V., de Miguel, Á. G., & Jiménez‐García, R. (2006) · Human Vaccines · doi:10.4161/hv.2756 · Cited by 12
Invasive Pneumococcal Infections
Backhaus, E. (2011) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 11
Immunofitness in the elderly: The role of vaccination in promoting healthy aging
Rial, J. G., Redondo, E., Calle, I. R., Mascarós, E., Ocaña, D., Jimeno, I., Gil, A., Linares, M., Onieva-García, M. Á., González‐Romo, F., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2624234 · Cited by 12
Crossley, K., & Peterson, P. K. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00314-3 · Cited by 10
Thornton, C. S., Brown, E. L., Alcantara, J., Rabin, H. R., & Parkins, M. D. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0041-z · Cited by 10
“Furthermore, the 23-valent vaccine does not reduce rates of pneumonia but rather is effective in preventing invasive disease such as meningitis and bacteremia [25].”
BackgroundSwiss primary care physicians reporting of utility and use of recommended vaccinations for adults
Chamot, E., & Bouvier, G. (2005) · Swiss Medical Weekly · doi:10.4414/smw.2005.10902 · Cited by 10
Chen, C.-H., Chen, C., Su, L. H. J., Chen, C., Tsai, M., & Chiu, C. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2497611 · Cited by 12
GAILLAT, J. (2009) · Expert Review of Respiratory Medicine · doi:10.1586/ers.09.53 · Cited by 9
Outbreaks of influenza B infection and pneumococcal pneumonia at a mental health facility in Japan
Yamazaki, Y., Goto, N., Iwanami, N., Hama, M., Fujiwara, N., Takahashi, Y., Sekiguchi, M., Chang, B., & Yamazaki, M. (2017) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2017.07.014 · Cited by 9
Decreasing invasive pneumococcal disease in the elderly: A state-level analysis
McBean, A. M., Jung, K., & Hebert, P. L. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.04.055 · Cited by 9
Peetermans, W. E. C., de Vyver, N. V., Laethem, Y. V., Damme, P. V., Thiry, N., Trefois, P., Geerts, P. A. F., Schetgen, M., Peleman, R. A., Swennen, B., et al. (2005) · Acta Clinica Belgica · doi:10.1179/acb.2005.050 · Cited by 8
Burke, M. (2018) · Current Geriatrics Reports · doi:10.1007/s13670-018-0258-9 · Cited by 7
Cruz‐Leal, Y., Menéndez, T., Coizeau, E., Espinosa, R., Canaán‐Haden, L., Blanco, F., Carmenate, T., Chang, J., Quiñones, D., Tamargo, I., et al. (2006) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20060007 · Cited by 6
Bacterial Polysaccharide Vaccines
AUSTRIAN, R. C. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1339-5_11 · Cited by 6
Adult vaccination in 11 Central European countries – Calendars are not just for children
Chlíbek, R., Anca, I., André, F., Čižman, M., Ivaškevičienė, I., Mangarov, A., Mészner, Z., Perenovska, P., Pokorn, M., Prymula, R., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.091 · Cited by 5
ECONOMIC EVALUATIONS OF PNEUMOCOCCAL VACCINATION STRATEGIES IN ADULTS. A SUMMARY OF THE RESULTS.
Thiry, N., Beutels, P., & Damme, P. V. (2005) · Acta Clinica Belgica · doi:10.1179/acb.2005.051 · Cited by 5
“Furthermore, if only a small degree of protection against pneumococcal pneumonia could be demonstrated (and this has been recently suggested [11]), efficiency of pneumococcal vaccination would even be more compelling.”
BackgroundPneumococcal vaccines: confronting the confounders
Jefferson, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61093-x · Cited by 5
Vila-Córcoles, Á., Gondar, O. O., Echeverría, X. A., Creixenti, J. B., Llamazares, L. P., & Fuentes-Bellido, C. M. (2005) · Revista Española de Salud Pública · doi:10.1590/s1135-57272005000600004 · Cited by 5
Carbohydrate-based anti-bacterial and anti-cancer vaccines
Das, R., & Mukhopadhyay, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816675-8.00014-2 · Cited by 4
Ergebnisse aus der biomedizinischen Alternsforschung
Pfister, G., Herndler‐Brandstetter, D., & Grubeck-Loebenstein, B. (2006) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-006-1278-8 · Cited by 4
Hypertension Management and Antihypertensive Withdrawal--A Perspective.
Mangrulkar, S., Khair, P., Hingne, V., & Hanchnale, P. (2015) · PubMed · Cited by 3
IMMUNOSENESCENCE - INEVITABLE OR PREVENTABLE?
Kalula, S., & Ross, K. A. (2008) · Cited by 3
Movsisyan, M., Harutyunyan, H. A., Kh, M., Kasparova, I., Hakobyan, A., & Yenkoyan, K. B. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112735 · Cited by 3
“These differences may be attributed to immunosenescence, chronic diseases, and reduced response to the vaccine (Goodwin et al., 2006; Kaml et al., 2006; Melegaro and Edmunds, 2004).”
Bacterial polysaccharide vaccines
Jennings, H. J., & Pon, R. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374546-0.00048-1 · Cited by 3
VACUNACIÓN EN EL ENFERMO RESPIRATORIO
Alfageme, I., Núñez, N. R., & Sánchez, M. M. (2005) · Neumosur: revista de la Asociación de Neumólogos del Sur · Cited by 3
Vila-Córcoles, Á., Gondar, O. O., Serrano, E. S., Navarro, A. V., & Luria, X. R. (2006) · Atención Primaria · doi:10.1157/13092990 · Cited by 2
Novel Strategies for Improved Vaccines for the Elderly: The Example of Influenza
Giudice, G. D., & Rappuoli, R. (2011) · Springer eBooks · doi:10.1007/978-3-0346-0219-8_10 · Cited by 2
“This pneumococcal polysaccharide vaccine has shown 50–70% efficacy against invasive pneumococcal disease in the general elderly population, which dropped, however, to 20% in high-risk elderly individuals [50].”
BackgroundCharacteristics of B Cells and B Cell Responses in Aged Individuals
Mei, H. E., & Radbruch, A. (2011) · Springer eBooks · doi:10.1007/978-3-0346-0219-8_4 · Cited by 2
“At the same time, aged individuals respond less frequently and less efficiently to common vaccinations [14], such as against tetanus [15], hepatitis B [16, 17], pneumococcal polysaccharides [18], and influenza [19–21], including mucosal vaccines [22].”
Pneumococcal Vaccines and Autoimmune Phenomena
Borella, E., Agmon‐Levin, N., Doria, A., & Shoenfeld, Y. (2015) · doi:10.1002/9781118663721.ch20 · Cited by 2
Vacunación antineumocócica en la población mayor de 65 años
Vila-Córcoles, Á. (2007) · Atención Primaria · doi:10.1157/13106279 · Cited by 2
Weinberger, B., & Grubeck‐Loebenstein, B. (2011) · Springer eBooks · doi:10.1007/978-3-0346-0219-8_8 · Cited by 2
“Nevertheless, vaccination of the elderly with PPV has been shown to be cost-effective [51].”
BackgroundBacterial Carbohydrate-Based Vaccines
Jones, C. (2007) · Elsevier eBooks · doi:10.1016/b978-044451967-2/00119-7 · Cited by 1
The Efficacy of Vaccines to Prevent Infectious Diseases in the Elderly
Herndler‐Brandstetter, D., & Grubeck‐Loebenstein, B. (2007) · Springer eBooks · doi:10.1007/978-0-387-76842-7_10 · Cited by 1
Adžić‐Vukičević, T., Rosic, I., Jovanović, D. M., & Medić, S. (2008) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh0812625a · Cited by 1
An Outbreak of Streptococcus pneumoniae Serotype 11A Pneumonia at a Nursing Home, Tokyo, 2009
Kikuchi, T., Sakamaki, F., Taniyama, D., Tsuchihashi, Y., Yamagishi, T., & Kitahara, M. (2014) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.88.149 · Cited by 1
Tan, L., & Theilacker, C. (2019) · Practical issues in geriatrics · doi:10.1007/978-3-030-05159-4_12 · Cited by 1
Veras, M. A. D. S. M. (2005) · doi:10.11606/t.5.2005.tde-10102014-102755 · Cited by 1
Klemets, P. (2009) · Työväentutkimus Vuosikirja · Cited by 1
Biology of Immune Responses to Vaccines in the Elderly
Weinberger, B., Herndler‐Brandstetter, D., Schwanninger, A., Weiskopf, D., & Grubeck‐Loebenstein, B. (2008) · ISBN · Cited by 1
Pfister, G., Herndler‐Brandstetter, D., & Grubeck-Loebenstein, B. (2006) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · Cited by 1
THE SCIENTIFIC PANEL ON VACCINES AND IMMUNISATION
Lopalco, P. L., & Giesecke, J. (2007) · Cited by 1
Development of improved diagnostic testing methods for invasive pneumococcal disease
Werno, A. (2013) · Otago University Research Archive (University of Otago) · Cited by 1
Ecology of virulence genes in the human pathogen Streptococcus pneumoniae
Johnston, C. (2008) · Enlighten: Theses (The University of Glasgow)
Diagnosis, prognosis and prevention of severe pneumococcal disease
Spindler, C. (2008) · Figshare
¿Tenemos en cuenta el nivel de riesgo de los pacientes para prescribir la vacuna antineumocócica?
Vila, A., Ochoa, O., Ester, F., Noguera, I., & Saun, N. (2006) · Medicina de Familia SEMERGEN · doi:10.1016/s1138-3593(06)73311-1
Erna Ripoll, M., Valenzuela, M. T., Rodrigo Vergara, F., Abarca, K., V, Alma Muñoz, M., de la Jara, J. J., Claude, M. E. P., & Vivian Luchsinger, F. (2010) · Revista chilena de infectología · doi:10.4067/s0716-10182010000200005
Chlíbek, R., Anca, I., Andre, F., Čižman, M., Ivaškevičienė, I., Mangarov, A., Mészner, Z., Perenovska, P., Pokorn, M., Prymula, R., et al. (2012) · Pediatria Polska · doi:10.1016/s0031-3939(12)70637-6
Les vaccins antipneumococciques chez l’adulte : où en sommes-nous ?
GAILLAT, J. (2012) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2012.04.004
Kolibab, K. (2005) · OhioLink ETD Center (Ohio Library and Information Network)
Revista chilena de infectología versão impressa ISSN 0716-1018
Ripoll, M., Teresa, M., Valenzuela, B., Muñoz, M., Eugenia, M., Pinto, C., & Luchsinger, F. V. (2010)
Le vaccin anti-pneumococcique polysaccharidique Pneumococcal polysaccharide vaccine
Laethem, Y. V. (2004)
Effects of Ageing on the Vaccination Response
Weinberger, B. (2016) · Springer eBooks · doi:10.1007/978-3-319-43365-3_5
La educación terapéutica en los pacientes con EPOC
Ayora, A. F. (2016) · doi:10.6035/14103.2016.442846
Wagar, L. E. (2013) · TSpace (University of Toronto)
Pneumococcal disease and the impact of pneumococcal conjugate vaccines
Wagenvoort, G. H. J. (2017) · Utrecht University Repository (Utrecht University)
Maladies bactériennes invasives dans le Nord du Canada de 2006 à 2013
Li, Y., Martin, I., Rs, T., Squires, S. G., Demczuk, W., & Desai, S. (2016) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v42i04a01f
“L’utilité et l’efficacité du Pneu-P-23, lequel diffère des vaccins conjugués, sont relativement plus faibles (24-26), et la protection que procure le Pneu-P-23 semble décliner après cinq ans (27).”
BackgroundGulin, M., Čivljak, R., Bubić, I., Knotek, M., & Miletić‐Medved, M. (2019) · Liječnički vjesnik · doi:10.26800/lv-141-3-4-9
Crossley, K., & Peterson, P. K. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00315-5
Post Vaccination Titers of Serum Anti-Diphtheria in Indonesian Young and Middle-Aged AdultsPreprint
Soegiarto, G., Novritasari, D., Baskoro, A., Fetarayani, D., & Nurani, W. K. (2021) · Preprints.org · doi:10.20944/preprints202107.0245.v1
Navarro, T., Wilson, R. C., Foxley, S., Blackler, L., Mooney, C., & Jones, C. (2007) · doi:10.1002/9780470697603.ch6
(CCNI), C. C. N. D. L. (2013) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v39i00a05f
CONTRAINDICATIONS FOR INFLUENZA VACCINATION
Sargur, R. B., & Egner, W. (2007) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715200737040205
Lockhart, S. P., & Ford, C. E. (2026) · Springer eBooks · doi:10.1007/978-3-032-37993-1_8
Metadata
- Authors
- Melegaro, A., & Edmunds, W. J.
- Affiliations
- University of Warwick (GB)
- City, University of London (GB)
- Corresponding author
- Melegaro, Alessia
- ORCID
- Melegaro, Alessia
- Venue
- European Journal of Epidemiology
- Published
- 2004-04
- Volume
- 19
- Issue
- 4
- Pages
- 353-363
- ISSN
- 0393-2990 (ISSN-L)
- 1573-7284
- OpenAlex
- W2010088615
- Cited by
- 185
- References
- 39
- Citations by year
- 2026: 2 · 2025: 2 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 11 · 2015: 9 · 2014: 8 · 2013: 13 · 2012: 15
- FWCI
- 10.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- European Journal of Epidemiology (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della Ricerca - Bocconi (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
- Keywords
- 23-valent pneumococcal polysaccharide vaccine, vaccine efficacy, older adults, invasive pneumococcal disease, pneumococcal pneumonia, high-risk groups
- MeSH terms
- Aged, Humans, Pneumococcal Infections, Pneumonia, Pneumococcal, Confidence Intervals, Odds Ratio, Randomized Controlled Trials as Topic, Risk Assessment, Pneumococcal Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
